AIB1 was initially found to be amplified in breast cancer [13], but was later also found to be amplified in other cancers [14], including ovarian cancers [15,16], endometrial carcinomas [17], pancreatic cancers [18] and prostate cancer [19]. Here, NCOA3 is linked to prostate cancer.